# Discovery Analysis - 2026-04-15 **LLM Provider**: GOOGLE **Models**: Shallow=gemini-2.5-flash-lite, Deep=gemini-3-pro-preview ## Top Investment Opportunities ### #1: ANAB **Company:** AnaptysBio **Current Price:** $70.22 **Strategy:** short_squeeze **Score:** 95 | **Confidence:** 9/10 | **Risk:** High **Description:** > Clinical-stage biopharmaceutical company focused on immunology and inflammation therapeutics. **Investment Thesis:** ANAB perfectly aligns a hard fundamental catalyst with an extreme short squeeze setup. The company's spin-off into First Tracks Biotherapeutics is effective April 20 (in 5 days), providing an urgent mechanism to force covering of the 30.6% short interest (9.8 days to cover). Technicals heavily support the upside, featuring a MACD bullish crossover, rising OBV (16.3M), and the price holding a strong 19.8% above its 50 SMA. The primary risk is high volatility (ATR of $4.18) and the potential for a 'sell the news' reaction post-spin-off. --- ### #2: ORCL **Company:** Oracle Corporation **Current Price:** $163.00 **Strategy:** technical_breakout **Score:** 88 | **Confidence:** 8/10 | **Risk:** Moderate **Description:** > Multinational computer technology corporation known for its enterprise software, cloud computing, and database products. **Investment Thesis:** ORCL recently broke out, closing 2.9% above its 20-day high on 2.5x average volume following news of an AI utility platform and a Bloom Energy partnership. The technical posture is highly robust, trading 8.8% above its 50 SMA with a fresh MACD bullish crossover and rising on-balance volume. The fundamental catalyst of AI monetization combined with heavy volume confirmation signals strong institutional sponsorship. The main risk is short-term mean reversion as it currently trades near the upper Bollinger Band (109% position). --- ### #3: RPAY **Company:** Repay Holdings **Current Price:** $3.07 **Strategy:** insider_buying **Score:** 82 | **Confidence:** 8/10 | **Risk:** Moderate **Description:** > Provider of integrated payment processing solutions to industry-specific markets. **Investment Thesis:** RPAY presents a compelling alignment of insider buying and activist pressure, with 10% owner Forager Fund recently purchasing $2.4M in stock. This coincides with the company adopting a poison pill to defend against activist accumulation, creating a strong fundamental floor and catalyst for value realization. Technicals show a supportive base with a MACD bullish crossover, rising OBV, and price trading 3.6% above the 50 SMA. Given its low share price, volatility is inherent, but the activist narrative heavily skews the risk/reward to the upside. --- ### #4: ARCT **Company:** Arcturus Therapeutics **Current Price:** $8.68 **Strategy:** short_squeeze **Score:** 78 | **Confidence:** 7/10 | **Risk:** High **Description:** > Clinical-stage mRNA medicines and vaccines company. **Investment Thesis:** ARCT screens exceptionally well for a short squeeze, heavily burdened with 31.5% of its float sold short and a massive 12.7 days to cover. Technical confirmation is highly present as the stock remains in a confirmed uptrend, trading 15.5% above its 50 SMA with rising on-balance volume and a bullish RSI of 67.1. Because of the extended days-to-cover ratio, any positive PR could ignite a rapid covering cycle. Binary biotech risks and a high ATR (5.5% of price) warrant careful position sizing. --- ### #5: SG **Company:** Sweetgreen **Current Price:** $6.20 **Strategy:** insider_buying **Score:** 76 | **Confidence:** 7/10 | **Risk:** High **Description:** > Fast-casual restaurant chain specializing in custom salads and warm bowls. **Investment Thesis:** SG saw heavy institutional conviction with Goldman Sachs acquiring $3.38M in stock, a massive signal for a company of this market cap. The technical setup strongly confirms this accumulation, featuring a MACD bullish crossover, rising OBV, and a strong uptrend (+11.1% above 50 SMA). The 8% intraday move indicates momentum is already aggressively accelerating. The primary risk is chasing the extended move near the upper Bollinger Band (97% position), which could lead to short-term pullbacks. --- ### #6: RPM **Company:** RPM International **Current Price:** $108.67 **Strategy:** pead_drift **Score:** 74 | **Confidence:** 7/10 | **Risk:** Low **Description:** > Manufacturer of specialty coatings, sealants, building materials, and related services. **Investment Thesis:** RPM delivered a massive 59.9% earnings surprise 7 days ago, leaving the window wide open for post-earnings announcement drift (PEAD). While the price has remained relatively flat over the last 5 days (-0.05%), the OBV is showing a bullish divergence (rising to 1.7M), indicating quiet institutional accumulation. The stock remains in a steady uptrend above its 50 SMA with low volatility (3.3% ATR). A failure to break near-term Fibonacci resistance at $110.76 could stall momentum, but downside appears limited. --- ### #7: NI **Company:** NiSource Inc. **Current Price:** $47.22 **Strategy:** volume_divergence **Score:** 72 | **Confidence:** 7/10 | **Risk:** Low **Description:** > Energy holding company providing natural gas and electricity. **Investment Thesis:** NI exhibits a classic multi-week accumulation setup, with OBV running +24.2% above average volume despite a relatively flat 20-day price trend. Technicals confirm the underlying institutional buying, showing a bullish OBV divergence (133.2M) and price holding 2.0% above the 50 SMA. This low-volatility (1.8% ATR) setup provides a safe, asymmetric entry for a defensive stock. The primary risk is macroeconomic sector rotation away from utilities if bond yields spike. --- ### #8: SRPT **Company:** Sarepta Therapeutics **Current Price:** $22.15 **Strategy:** social_dd **Score:** 70 | **Confidence:** 6/10 | **Risk:** Moderate **Description:** > Commercial-stage biopharmaceutical company focused on precision genetic medicine. **Investment Thesis:** SRPT combines strong social sentiment with excellent technical confirmation, trading in a steady uptrend 17.2% above its 50 SMA. Momentum indicators are heavily supportive, with a bullish MACD, rising OBV (52.8M), and price holding comfortably above the 20 EMA. The 'social_dd' scanner's 55% historical 30-day win rate adds statistical edge to the setup. As with any biotech, unforeseen clinical or regulatory developments remain the primary downside risk. --- ### #9: RELL **Company:** Richardson Electronics **Current Price:** $13.56 **Strategy:** pead_drift **Score:** 68 | **Confidence:** 6/10 | **Risk:** High **Description:** > Distributor of electronic components and enterprise computing solutions. **Investment Thesis:** RELL is in the midst of a strong PEAD move after beating earnings estimates by 52.5% 7 days ago. The stock is up 15.3% over the last 5 days, supported by rising OBV (4.0M) and a bullish MACD, and is trading firmly above its 50 SMA (+12.5%). While the momentum is powerful, the stock is trading near its upper Bollinger Band (92% position) with high volatility (6.5% ATR), which warrants caution against sudden mean-reversion pullbacks. --- ### #10: DTE **Company:** DTE Energy **Current Price:** $147.74 **Strategy:** volume_divergence **Score:** 68 | **Confidence:** 6/10 | **Risk:** Low **Description:** > Diversified energy company involved in the development and management of energy-related businesses. **Investment Thesis:** DTE shares a highly similar setup to NI, showing a clear bullish OBV divergence (+23.9% of avg vol) against a flat 20-day price trend. The technical posture is resilient, with the stock in a strong uptrend and trading 2.4% above its 50 SMA. With earnings approaching in 8 days, this quiet accumulation suggests institutions are positioning for a strong print. The extremely low ATR (1.7%) makes this a defensive play, though the impending earnings date introduces binary event risk. --- ## All Candidates Analyzed Total candidates analyzed: 10 - **ANAB** (short_squeeze) - **ORCL** (technical_breakout) - **RPAY** (insider_buying) - **ARCT** (short_squeeze) - **SG** (insider_buying) - **RPM** (pead_drift) - **NI** (volume_divergence) - **SRPT** (social_dd) - **RELL** (pead_drift) - **DTE** (volume_divergence)